Important Update: Vyepti

During recent communications, we have received this update from Lundbeck regarding Vyepti

To achieve optimum efficiency for patients and doctors Lundbeck Australia has decided to extend the Special Access Scheme (SAS) for Vyepti® (eptinezumab) until 31st December 2021 when last registrations will take place. Existing patients can continue on the program until 21st January 2022.
From 24th January 2022, Vyepti® will be available on private prescription from a treating neurologist with an estimated cost to patient of between $1,700 and $1,800 per quarter.

Lundbeck is progressing an application to the PBAC for PBS listing of Vyepti®.
We know the cost of Vyepti will be concerning for many of our members and supporters, as a private script Vyepti should be available on Non PBS Pharmaceuticals via your Extras on Private Health Insurance if you have it.

Information on access to Vyepti® (eptinezumab)
Issued 4th February 2022

Lundbeck Australia has extended access to Vyepti® (eptinezumab) for patients enrolled in the Special Access Scheme (SAS) who started Vyepti treatment in 2021. Eligible patients already enrolled in the Program will continue to receive their Vyepti infusions free of charge. There will be no new patient enrolments into the Program.

Lundbeck is monitoring the current situation in the healthcare system and determining the most appropriate time to make Vyepti broadly available for prescribing.
As soon as we have more news for you regarding Vyepti we will let you know. If you would like to read more about Vyepti and other CGRPs, visit

Please donate what you can today so we can fight harder for the CGRPs. Every dollar counts!
You can also consider starting a donation appeal of your own on Facebook - it's easy to do! Simply click here!

Showing 2 reactions

  • Anonymous
    followed this page 2022-01-02 11:04:02 +1000
  • Sarah Moseley
    published this page in News 2021-11-11 17:48:20 +1000